Key result
Transapical aortic valve implantation with the Edwards bioprosthesis achieved a 96.7% procedural success rate, with actuarial survival rates of 73.8%, 67.2%, and 41.0% at 1, 2, and 4 years.
Why the study?
What are the 4-year outcomes of transapical TAVI with the Edwards bioprosthesis in high-risk patients unsuitable for conventional surgery or transfemoral access?
Cohort (n=61)
No
What are the 4-year outcomes of transapical TAVI with the Edwards bioprosthesis in high-risk patients unsuitable for conventional surgery or transfemoral access?
Transapical TAVI with the Edwards bioprosthesis provides satisfactory long-term outcomes in high-risk patients unsuitable for conventional surgery or transfemoral access.
Answers are grounded in this paper and cite their sources.
May support transapical TAVI in select high-risk patients; leaves open need for randomized comparisons.
BACKGROUND: The first French transapical transcatheter aortic valve implantation (TAVI) was performed in July 2007 in our department. AIMS: To report 4-year outcomes of transapical implantation with the Edwards transcatheter bioprosthesis. METHODS: We prospectively evaluated consecutive patients who underwent transapical implantation with an Edwards transcatheter bioprosthesis between July 2007 and October 2011. Patients were not suitable for conventional surgery (due to severe comorbidities) or transfemoral implantation (due to poor femoral access). RESULTS: Among 61 patients (59.0% men), mean logistic EuroSCORE was 27.5 ± 14.9% and mean age was 81.0 ± 6.8 years. Successful valve implantation was achieved in 59/61 patients (96.7%) of patients. The other two patients required conversion to conventional surgery due to prosthesis embolization and died. Six additional patients died in the postoperative period. Causes of perioperative death were two septic shocks (one of peritonitis), two multi-organ failure, one ventricular fibrillation and one respiratory insufficiency. Intraprocedural stroke was not observed in any patient. The actuarial survival rates at 1, 2 and 4 years were 73.8%, 67.2% and 41.0%. During this 4-year period, four patients died of cardiovascular events, but no impairment of transprosthesis gradient was observed. CONCLUSION: Our series of 61 patients who underwent transapical implantation of the Edwards transcatheter bioprosthesis shows satisfactory results, similar to other reports, considering the high level of severity of patients referred for this method. Transapical access is a reliable alternative method for patients that cannot benefit from a transfemoral approach.
No takes yet. Share an insight, caveat, or question.
Litzler et al. (2012) conducted a cohort in Aortic valve disease unsuitable for conventional surgery or transfemoral implantation (n=61). Transapical transcatheter aortic valve implantation (TAVI) with Edwards bioprosthesis was evaluated on Successful valve implantation. Transapical aortic valve implantation with the Edwards bioprosthesis achieved a 96.7% procedural success rate, with actuarial survival rates of 73.8%, 67.2%, and 41.0% at 1, 2, and 4 years.
Synapse has enriched 10 related papers. Consider them for comparative context: